BACKGROUND: The majority of patients with hepatitis C virus (HCV) infection suffer from disabling fatigue, cognitive dysfunction, and quality of life reduction. Meanwhile, there is increasing evidence that HCV infection can affect brain function. Recent studies have shown that fatigue and psychomotor slowing may resolve in patients with hepatitis C after treatment with ondansetron. This observation indicates alteration of serotonergic neurotransmission in HCV infected patients with chronic fatigue. METHODS: Data from 20 HCV infected patients who were referred to our clinic because of disabling fatigue and cognitive decline of unknown cause were analysed retrospectively. Patients had undergone a diagnostic programme, including clinical and psychometric examination, electroencephalogram (EEG), magnetic resonance imaging of the brain, cerebrospinal fluid analysis, and I-123-beta-CIT (2beta-carbomethoxy-3-beta-(4-[(123)I]iodophenyl)tropane) single photon emission computerised tomography (SPECT) studies of serotonin and dopamine transporter binding capacity. RESULTS: All patients had pathological results on the fatigue impact scale. Two thirds of patients showed pathological attention test results. EEG, magnetic resonance imaging, and cerebrospinal fluid analysis were normal. Pathological dopamine transporter binding was present in 12/20 (60%) patients and pathological serotonin transporter binding in 8/19 (50%) patients. Patients with normal SPECT results did not significantly differ from controls with regard to psychometric test results. Interestingly, patients with both decreased serotonin and dopamine transporter binding showed significantly impaired performance in most of the tests applied. Comorbidity that could have impaired cerebral function was excluded in all patients. CONCLUSION: Our findings indicate alteration of serotonergic and dopaminergic neurotransmission in HCV infected patients with chronic fatigue and cognitive impairment.
BACKGROUND: The majority of patients with hepatitis C virus (HCV) infection suffer from disabling fatigue, cognitive dysfunction, and quality of life reduction. Meanwhile, there is increasing evidence that HCV infection can affect brain function. Recent studies have shown that fatigue and psychomotor slowing may resolve in patients with hepatitis C after treatment with ondansetron. This observation indicates alteration of serotonergic neurotransmission in HCV infectedpatients with chronic fatigue. METHODS: Data from 20 HCV infectedpatients who were referred to our clinic because of disabling fatigue and cognitive decline of unknown cause were analysed retrospectively. Patients had undergone a diagnostic programme, including clinical and psychometric examination, electroencephalogram (EEG), magnetic resonance imaging of the brain, cerebrospinal fluid analysis, and I-123-beta-CIT (2beta-carbomethoxy-3-beta-(4-[(123)I]iodophenyl)tropane) single photon emission computerised tomography (SPECT) studies of serotonin and dopamine transporter binding capacity. RESULTS: All patients had pathological results on the fatigue impact scale. Two thirds of patients showed pathological attention test results. EEG, magnetic resonance imaging, and cerebrospinal fluid analysis were normal. Pathological dopamine transporter binding was present in 12/20 (60%) patients and pathological serotonin transporter binding in 8/19 (50%) patients. Patients with normal SPECT results did not significantly differ from controls with regard to psychometric test results. Interestingly, patients with both decreased serotonin and dopamine transporter binding showed significantly impaired performance in most of the tests applied. Comorbidity that could have impaired cerebral function was excluded in all patients. CONCLUSION: Our findings indicate alteration of serotonergic and dopaminergic neurotransmission in HCV infectedpatients with chronic fatigue and cognitive impairment.
Authors: N D Volkow; R C Gur; G J Wang; J S Fowler; P J Moberg; Y S Ding; R Hitzemann; G Smith; J Logan Journal: Am J Psychiatry Date: 1998-03 Impact factor: 18.112
Authors: G Berding; Th Brücke; P Odin; D J Brooks; H Kolbe; P Gielow; H Harke; B O Knoop; R Dengler; W H Knapp Journal: Nuklearmedizin Date: 2003-02 Impact factor: 1.379
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: J T Kuikka; J Tiihonen; K A Bergström; J Karhu; P Hartikainen; H Viinamäki; E Länsimies; J Lehtonen; P Hakola Journal: Eur J Nucl Med Date: 1995-04
Authors: David A Sheridan; S H Bridge; M M E Crossey; D J Felmlee; H C Thomas; R D G Neely; S D Taylor-Robinson; M F Bassendine Journal: Metab Brain Dis Date: 2014-03-12 Impact factor: 3.584
Authors: Edna Strauss; Francisco Augusto Porto-Ferreira; Cesar de Almeida-Neto; Maria Cristina Dias Teixeira Journal: Clin Res Hepatol Gastroenterol Date: 2013-11-14 Impact factor: 2.947
Authors: Sarah L Fishman; Jacinta M Murray; Francis J Eng; José L Walewski; Susan Morgello; Andrea D Branch Journal: J Infect Dis Date: 2008-02-15 Impact factor: 5.226